<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Tang, Fengyuan</dc:creator>
  <dc:creator>Wang, , Yuhua</dc:creator>
  <dc:creator>Hemmings, Brian A.</dc:creator>
  <dc:creator>Rüegg, Curzio</dc:creator>
  <dc:creator>Xue, Gongda</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Chronic inflammation is a major cause of human cancer. Clinical cancer therapies  against inflammatory risk factors are strategically determined. To rationally guide a  novel drug development, an improved mechanistic understanding on the pathological  connection between inflammation and carcinogenesis is essential. PI3K-PKB signaling  axis has been extensively studied and shown to be one of the key oncogenic drivers in  most types of cancer. Pharmacological inhibition of the components along this signaling  axis is of great interest for developing novel therapies. Interestingly, emerging studies  have shown a close association between PKB activation and inflammatory activity in  the vicinity of the tumor, and either blockade of PKB or attenuation of para-tumoral  inflammation reveals a mutual-interactive pattern through pathway crosstalk. In this  review, we intend to discuss recent advances of PKB-regulated chronic inflammation  and its potential impacts on tumor development.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305744</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305744/files/rue_pdr.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.semcancer.2017.04.018</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Seminars in Cancer Biology. - 2018, vol. 48, p. 62-69</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Protein kinase B</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Oncogenic signaling</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Chronic inflammation</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Immunogenic cancer progression</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Intratumoral immune response</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Immune surveillance</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">PKB/Akt-dependent regulation of inflammation in cancer</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>